Valuation: Ardelyx, Inc.

Market Cap 1.21B 1.05B 986M 902M 1.7B 116B 1.72B 11.53B 4.53B 57.73B 4.55B 4.46B 192B P/E 2026 *
-77.9x
P/E 2027 * 10.8x
Enterprise Value 1.21B 1.05B 986M 902M 1.7B 116B 1.72B 11.53B 4.53B 57.73B 4.55B 4.46B 192B EV / Sales 2026 *
2.24x
EV / Sales 2027 * 1.64x
Free-Float
96.74%
Yield 2026 *
-
Yield 2027 * -
1 day-0.81%
1 week-2.60%
Current month-1.62%
1 month-7.59%
3 months-31.70%
6 months-30.43%
Current year-16.47%
1 week 4.82
Extreme 4.815
5.1
1 month 4.82
Extreme 4.815
5.56
Current year 4.82
Extreme 4.815
8.4
1 year 4.71
Extreme 4.7101
8.4
3 years 3.16
Extreme 3.16
10.13
5 years 0.49
Extreme 0.4902
10.13
10 years 0.49
Extreme 0.4902
16.3
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2009
Director of Finance/CFO 55 04/11/2025
Chief Tech/Sci/R&D Officer 50 01/04/2026
Director TitleAgeSince
Director/Board Member 61 01/03/2009
Chairman 60 01/03/2014
Director/Board Member 59 01/03/2014
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Fiscal year

Chief Executive Officer

83,336 0.0337%
24/02/26 Fiscal year

Chief Executive Officer

83,332 0.0343%
20/02/26 Sell

Chief Technology Officer

3,179 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%-2.60%-5.07%+24.55% 1.21B
-3.25%+12.81%+52.96%+88.86% 64.9B
+0.69%-2.81%+25.84%+68.41% 54.05B
-1.07%-1.89%-17.90%-14.36% 23.16B
+33.86%+28.54%+18.76%+502.77% 21.46B
+1.87%+5.08%+29.88%-7.94% 21.25B
-0.79%+0.54%+31.17%-25.84% 17.94B
-3.37%+19.44%+211.98%+369.13% 17.03B
+3.29%+2.09%+17.32%+586.49% 14.99B
-7.94%-5.66%+39.35%+157.52% 14.25B
Average +2.30%+2.85%+40.43%+174.96% 25.02B
Weighted average by Cap. +1.76%+3.61%+41.72%+146.42%

Financials

2026 *2027 *
Net sales 541M 469M 440M 402M 759M 51.54B 769M 5.14B 2.02B 25.75B 2.03B 1.99B 85.7B 740M 642M 601M 550M 1.04B 70.45B 1.05B 7.03B 2.76B 35.2B 2.78B 2.72B 117B
Net income -15.26M -13.24M -12.4M -11.34M -21.41M -1.45B -21.69M -145M -56.92M -726M -57.28M -56.04M -2.42B 119M 103M 96.61M 88.37M 167M 11.33B 169M 1.13B 444M 5.66B 446M 437M 18.83B
Net Debt - -
Logo Ardelyx, Inc.
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.
Employees
489
Date Price Change Volume
07/08/26 $4.870 -0.81% 6,729,413
05/08/26 $4.910 -2.00% 3,109,709
04/08/26 $5.010 +0.60% 3,130,089
03/08/26 $4.980 +0.61% 2,919,404
31/07/26 $4.950 -1.79% 2,762,690
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.910USD
Average target price
16.30USD
Spread / Average Target
+231.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARDX Stock